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Nacre, 14032 CAEN Cedex, France.Through its associated cartilage breakdown, osteoarthritis
(OA) generally results in severe handicap and significant
pain. This common joint disease affects about 10% of the
world population, including an estimated 50% of people
over 60 years of age. By the age of 75, more than 80% of
people actually have symptoms of the disease. Approxi-
mately 16 million Americans suffer from this condition,1 and
the social cost of the disease has reached impressive
figures. Therefore, it is easily understandable that there is
considerable research into seeking out effective therapies.
Unfortunately, as is often the case for multifactorial dis-
eases, it has been hitherto difficult to clearly define
the best target(s) to address, although great progress has
been made in the knowledge of cellular and molecular
mechanisms underlying cartilage erosion.
The most important discovery in that field was the
demonstration, about fifteen years ago, that the cytokine
interleukin-1 (IL-1) plays a crucial role in the catabolic
process of OA articular cartilage.2,3 Using in-vitro cultures
of synovial cells and chondrocytes, this cytokine (also
called ‘monocyte cell factor’ or ‘catabolin’ at that time) was
shown to be capable of inducing expression of degrading
enzymes, the metalloproteases, and suppressing synthesis
of the major cartilage matrix macromolecules, collagen
type II and aggrecan.4–7 Since that time, and because of its
detrimental effect on cartilage, the IL-1 system and its
induced effects on chondrocytes became almost the
exclusive target for defining new and future therapeutic
approaches. Indeed, considerable efforts are still being
made to produce inhibitors of matrix metalloproteases that
are induced by IL-1 and/or to reduce the specific binding of
IL-1 on the joint cells, taking advantage for example, of
the IL-1 receptor antagonist (IL-1 RA) more recently dis-
covered. Interestingly enough, some attempts at genetic
therapy in animal models using cells over-expressing IL-1
RA have provided promising preliminary results.8
However, an alternative approach to define a new con-
cept of OA treatment should perhaps pay greater attention
to the repair potentialities of cartilage and to factors that
could antagonize the catabolic and anti-anabolic effects of
IL-1. Although adult articular cartilage has got a limited
ability to regenerate defects caused by injured or degen-
erative events, we must bear in mind that studies on the
early stages of OA, principally in animal models in which
they are easier to investigate, have revealed a repair
response of the cartilage to the primary lesions, reflected439by activation and clustering of chondrocytes and enhanced
proteoglycan synthesis.9–11 Unfortunately, this process
vanishes with time, being progressively overwhelmed by
the catabolic events. However, one key issue in developing
tools that could favor the repair potentialities of cartilage
and perhaps make them last longer, would be to determine
the exact role played by local growth factors in these
mechanisms and their relationship with cytokines like IL-1.
In the recent years, it has been demonstated that TGF-â
may play a pivotal role as it can enhance matrix production
and modulate chondrocyte proliferation.12 TGF-â can also
counter the IL-1-induced effects on expression of metallo-
proteases and matrix molecules and down-regulate the
expression of IL-1 receptor in articular chondrocytes.13
However, all these data have been obtained using in-vitro
cultures of chondrocytes and, in the absence of information
about the in-situ expression of TGF-â and its receptors in
the osteoarthritic cartilage, it was rather difficult to conclude
about the role this factor plays in the development of the
disease.
Interestingly, two recent reports using different
approaches make an important contribution towards
understanding how changes in the expression of TGF-â
receptors on the chondrocyte surface may explain the
progressive decrease of the metabolic activity of cartilage
and its failure to counter the deleterious IL-1 effects. In the
first one,14 RT-PCR analysis clearly demonstrated that
steady-state levels of mRNA for TGF-â receptor type II
(TâR-II) are dramatically reduced to almost undetectable
amounts at the end of the hypertrophic step of cartilage and
at later stages of the degraded tissue in a rabbit OA model
(section of cruciate ligament). Given that TâR-II is
absolutely necessary to bind TGF-â, before forming a
heteromeric complex with TâR-I which transmits the
signal,15 this finding suggests that such down-regulation
probably results in reduced sensitivity of the articular
chondrocytes to TGF-â during development of the OA
process. A diminished responsiveness of OA chondrocytes
would explain, at least partially, that repair potential of
altered cartilage is no longer capable of balancing the
erosive process and that irreversible degradation takes
place. This hypothesis recently received strong support
from the paper of Serra et al.,16 who have generated
transgenic mice that express a truncated, kinase-defective
TGF-â type II receptor, acting as a dominant negative
mutant, in their skeletal tissue (periosteum/perichondrium,
synovium and articular cartilage). They observed that these
mice develop a degenerative joint disease resembling
osteoarthritis in humans, as judged by histology of the
affected joints and alteration of proteoglycan and collagen
440 Editorialexpression. These two reports thus support the idea that
loss of responsiveness to TGF-â promotes osteoarthritis
and suggest that one of roles of endogenous TGF-â is to
maintain the integrity of the articular cartilage and perhaps
aid in its regeneration after injury.
So, this recent finding may have some impact on our
understanding of osteoarthritis mechanisms and restora-
tion of TGF-â receptor II expression in OA chondrocytes
might be a future objective in the treatment of the disease
that could delay the degradative evolution of the cartilage,
beside the attempts to block IL-1 effects. Since grafts of
autologous chondrocytes have been already performed
with some sucess to treat cartilage defects of human
knees,17 one can imagine also that, in the future, such
chondrocytes could be previously genetically modified to
over-express TGF-â receptor II (‘super-chondrocytes’) and
used to repair traumatical injuries of cartilage. Furthermore,
it would not be surprising that scientists take advantage of
the recent knowledge on molecules implicated in the TGF-â
signalling (particularly the smad proteins family)18 to modu-
late these pathways in order to restore the sensitivity of OA
chondrocytes to TGF-â. A new field is perhaps open for
chondroprotection and repair of cartilage in joint diseases.
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